Vaxcyte

Vaxcyte’s cell-free protein synthesis platform enables us to overcome limitations of traditional chemistry and develop potentially superior and novel vaccine candidates. With this unique technology, we are advancing our broad-spectrum pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31, that are designed to prevent invasive pneumococcal disease, as well as vaccines to potentially address bacterial diseases like Group A Strep and Shigella for which there are no preventative treatments.   Vaxcyte's Chief Executive Officer and Co-Founder Grant Pickering and Vice President of Research and Co-Founder Jeff Fairman share more about our platform, as well as our team's chemistry, which fuels our collaborative culture and drives our innovation. Learn more at vaxcyte.com/approach  #VaccineInnovation #vaccines #culture 

At Vaxcyte, we value moments that bring us together. Last week, our team members took a break from work to participate in and cheer on their colleagues during our first-ever Vaxcyte Cornhole Tournament. It was a fantastic afternoon filled with good weather, great company and lots of fun and bullseyes! Congratulations to our cornhole champions JD Aurellano and Harsha Lakshmankumar and a special shoutout to Itzel Garcia-Ocampo who won best form! #culture #biotech 

We’re excited to honor Mark Iverson, Senior Staff Scientist, Protein, who received Vaxcyte’s Powering Beyond Legacy Award. This award honors an individual who consistently models all four of our Vaxcyte core values over a significant period, leaving a meaningful impact. Throughout his seven years at Vaxcyte, Mark has constantly demonstrated the values of Aim High, Lead with Heart, Rethink Convention and Model Excellence. Beyond the lab, Mark has also been an active member of our culture club for years, helping to create opportunities for Vaxcyte team members to connect. Thank you, Mark, for your dedication to supporting Vaxcyte’s mission, culture and team!  

We are pleased to share our first quarter 2024 business and financial update as we continue to make meaningful progress across our business, particularly in advancing our pneumococcal conjugate vaccine (PCV) candidates, VAX-24 and VAX-31, which are intended to deliver the broadest-spectrum of coverage against invasive pneumococcal disease. We look forward to sharing the expected VAX-31 adult Phase 1/2 study topline data in the third quarter of this year and our first VAX-24 infant Phase 2 study topline data by the end of the first quarter of 2025. Together, these milestones will provide significant insight into our PCV franchise’s ability to achieve its full potential across the adult and pediatric populations. Read more here: https://lnkd.in/gjrrD6VY #biotechnology #vaccines #publichealth

Last week our team welcomed Vaxcyte employees and their children to our first-ever Take Your Kids to Work Day and it was a blast! We enjoyed introducing the kids to how we are working to prevent bacterial illnesses by developing innovative vaccines, conducting kid-friendly lab experiments, and celebrating together with lunch and festivities. It was a treat to share the Vaxcyte community and see so many kids excited about science. One child noted, “It was really cool to learn more about DNA by doing an experiment where we got to extract DNA from a strawberry! And, I got to understand how the company is developing vaccines." Thanks to all participants for joining and making it a memorable day, and a special shoutout to our team members who put a great deal of thought and care into making this day possible!

We’re thrilled to recognize Karen Lo, Director, IP Counsel, who was awarded Vaxcyte’s Powering Beyond Award in the category of Rethink Convention! Karen constantly personifies this Vaxcyte value through her creative approach to her work on our legal team. Her innovative thinking and inventive problem-solving methods encourage us all to incorporate diverse perspectives and embrace new strategies as we collectively work to engineer high-fidelity vaccines. Karen, we’re so grateful for your two years of service and dedication to Rethinking Convention at Vaxcyte!  

As a vaccine innovation company, Vaxcyte is dedicated to developing vaccines with the goal of eradicating or treating invasive bacterial infections. This World Immunization Week, we are highlighting the risks associated with such life-threatening bacterial diseases, including antimicrobial resistance (AMR). Over the last several years, AMR has emerged as an increasingly serious public health issue that if left unaddressed, will continue to have significant consequences and contribute to millions of deaths worldwide each year. Public health experts have urged action to combat AMR, including the increased use of vaccines to prevent infections. World Immunization Week reinforces the need to align forward-thinking vaccine innovation with public health needs. At Vaxcyte, our goal is to create vaccines that protect more children and adults from the consequences of bacterial diseases, while helping to address AMR in the process. Learn more about our mission at vaxcyte.com/mission. #WorldImmunizationWeek #Vaccines #AMR 

Congratulations to Marc Wong, Associate Director, Polysaccharide Process Development, who received Vaxcyte’s Powering Beyond Award in the category of Model Excellence. Since joining Vaxcyte three years ago, Marc has made significant contributions to the development and optimization of our pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. Marc’s commitment to enhancing our processes has been pivotal as we pursue our ambitious journey to protect humankind. We’re immensely thankful to Marc for Modeling Excellence and his many contributions to our team!  

At Vaxcyte, we are driven by a bold goal to protect infants and adults from the threat of infections caused by bacterial diseases. By working to expand the role vaccines play in treating such diseases, we aim to tackle one of the greatest public health challenges of the 21st century. Learn more about our mission at https://lnkd.in/gtQEyevr.

Join us in celebrating April Ruiz, Associate Director, HR Business Partner, who received Vaxcyte’s Powering Beyond Award for exemplifying the core value of Lead with Heart! April has made a huge impact on our company and culture during her nearly two years at Vaxcyte, always guiding with empathy and kindness. Her inclusive, human-first approach to collaboration empowers our employees and teams as they work to achieve their business objectives. April, we appreciate you for showing us what it means to Lead with Heart!